A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: [¹⁴C]Enlicitide chloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT06658626

0616-016

MK-0616-016 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to learn what happens to enlicitide chloride labeled with [¹⁴C] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Is in good health.
• Has a body mass index ≥18 and ≤32 kg/m^2, inclusive.

Exclusion criteria

• Has a history of cancer.
• Has positive tests for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

[¹⁴C]Enlicitide chloride

Experimental group

Description:

Participants will receive a single dose of \[¹⁴C\]enlicitide chloride on Day 1.

Treatment:

Drug: [¹⁴C]Enlicitide chloride